Kornimate/medical-research-clean huggingface dataset:
freeze-dried, capsulized fmt for rcdi

Conditions: Clostridium Difficile Infection

Summary: recurrent or refractory clostridium difficile infection (rcdi), with a recent increased incidence, is one of the most difficult and increasingly challenges for cdi. since fecal microbiota transplantation (fmt) has been accepted as the first-line therapy for rcdi, it is prudent to consider less invasive and more convenient means of administering fmt. the majority of reported fmt procedures have been performed with fresh or frozen stool suspensions via colonoscopy or nasojejunal tube. nowadays, using acid-resistant hypromellose capsules, youngster et al. significantly simplified the clinical practice of fmt and removed the need for invasive gastrointestinal procedures. however, to avoid undesirable disintegration, those capsules containing stool suspensions must be kept frozen all the time, which extremely limits their widespread application. the purpose of this study is to evaluate the efficacy and safety of freeze-dried, capsulized fmt for rcdi.


Eligibility criteria:
inclusion criteria: * patients with refractory, recurrent or relapsing c. difficile infection (rcdi), as defined in guidelines as a relapse of cdi after having at least 3 episodes of mild to moderate cdi and failure of a 6- to 8-week taper with vancomycin with or without an alternative antibiotic or at least 2 episodes of severe cdi resulting in hospitalization and associated with significant morbidity; * willingness to accept risk of healthy unrelated donor stool. exclusion criteria: * delayed gastric emptying syndrome; * known chronic aspiration; * swallowing dysfunction or oral-motor dyscoordination; * pregnant or breast-feeding women; * usage of probiotics, prebiotics or synbiotics within the last month; * smoking or alcohol use within the last month; * patients with an exacerbation of condition not because of cdi; * patients on major immunosuppressive agents or with any other cause of severe immunodeficiency; * patients with a history of significant allergy because of diet; * patients on any agents affecting fecal bacteriology because of comorbidities.

Keywords: clostridium difficile infection fecal microbiota transplantation freeze-dried acid-resistant capsules
pancreatic duct stent for acute necrotizing pancreatitis

Conditions: Necrotizing Pancreatitis; Walled Off Necrosis

Summary: the research design is a randomized prospective clinical study comparing the incidence of walled off necrosis (won) in patients with acute necrotizing pancreatitis.

this is a randomized trial comparing the incidence of won in patients with acute necrotizing pancreatitis, according to the placement or non-placement of an advanix or a cook pancreatic duct (pd) stent during endoscopic retrograde cholangiopancreatography (ercp) within 1-2 week of symptom onset. patients will be randomly allocated to either treatment arm i.e. to either pd stent placement or no pd placement in a 1:1 ratio. the type of stent to be placed is at the discretion of the physician based on the clinical needs and presentation of the patient at the time of procedure. this is based on factors such as the size of the won, the patient's anatomy, and other variables. patients will be assessed at 4-6 weeks post-ercp for the primary outcome measure, which is the incidence of won on contrast-enhanced ct.

Eligibility criteria:
inclusion criteria: 1. age ≥ 19 years 2. the subject (or when applicable the subject's lar) is capable of understanding and complying with protocol requirements. 3. the subject (or when applicable the subject's lar) is able to understand and willing to sign an informed consent form prior to the initiation of any study procedures. 4. all patients with acute necrotizing pancreatitis and bedside index for severity in acute pancreatitis (bisap) score of ≥ 3, who have been referred to florida hospital for percutaneous endoscopy gastrojeunostomy (peg-j) tube placement and/or ercp for assessment of the pd 5. absence of pancreatic fluid collection (defined as those \> 3cm in size located along the course of the main pd on cross-sectional imaging) at the time of study enrollment 6. no disconnected pancreatic duct syndrome (dpds) on cross-sectional imaging or ercp exclusion criteria: 1. age \<19 years 2. unable to obtain consent for the procedure from either the patient or lar 3. patients with acute interstitial pancreatitis, without pancreatic necrosis 4. patients with bisap score ≤ 2 5. patients with pancreatic fluid collection \> 3cm in size located along the course of the main pd on cross-sectional imaging prior to the initial ercp 6. patients with dpds on cross-sectional imaging or ercp 7. unable to safely undergo ercp for any reason 8. failed cannulation during ercp
real world perspectives on advancements in hearing aid technology

Conditions: Hearing Loss

Summary: this study will compare different microphone technologies in a noisy environment when the dominant speaker is at the front, back, left, or right side of the listener.

understanding speech in a noisy environment can be difficult for people with hearing loss even with hearing aids. hearing aid manufacturers have implanted various methods (i.e., directional micro-phones, noise reduction, noise cancelers) to try to improve the signal-to-noise ratio (snr) to increase the speech understanding in these difficult listening situations. this study is evaluating different microphone technologies to determine listening effort when speech is to the back or side of the listener in noisy environment.

Eligibility criteria:
inclusion criteria: * moderate sensorineural hearing loss * experienced hearing aid user * has a significant other/communication partner that can fill out a questionnaire about hearing aid performance during the home trial * smartphone user for receiving study alerts exclusion criteria: * cognitive impairment * not willing to wear hearing aid
digital diabetes treatment - the healthy eating, healthy patients trial

Conditions: Type 2 Diabetes

Summary: unhealthy diet is a major target in the prevention and treatment of type 2 diabetes (t2d) but access to dieticians in primary care is limited. while mobile health (mhealth) tools have been shown to improve diet and clinical management of patients with t2d, there are currently no such mhealth tools for patients with t2d in sweden. the key limitation of existing mhealth tools is that they provide generic dietary advice that is often difficult to implement in practice (e.g., non-specific suggestions to choose low-sugar products). the george institute for global health (sydney, australia) as developed the foodswitch mobile phone application (app), which suggests healthier food choices to consumers after scanning of packaged food items in the grocery store. in the digital diabetes treatment - the healthy eating, healthy patients trial (diatest-help), we will adapt the foodswitch app for use in sweden, and study the effect on glycated haemoglobin (hba1c), blood lipids, and low-grade inflammation in individuals with t2d using a randomized controlled trial design.

unhealthy diet is a major target in the prevention and treatment of type 2 diabetes (t2d) but access to dieticians in primary care is limited. while mobile health (mhealth) tools have been shown to improve diet and clinical management of patients with t2d, there are currently no such mhealth tools for patients with t2d in sweden. the key limitation of existing mhealth tools is that they provide generic dietary advice that is often difficult to implement in practice (e.g., non-specific suggestions to choose low-sugar products). the george institute for global health (sydney, australia) as developed the foodswitch mobile phone application (app), which suggests healthier food choices to consumers after scanning of packaged food items in the grocery store. in the digital diabetes treatment - the healthy eating, healthy patients trial (diatest-help), we will adapt the foodswitch app for use in sweden, and study the effect on glycated haemoglobin (hba1c), blood lipids, and low-grade inflammation in individuals with t2d using a randomized controlled trial design.

Eligibility criteria:
inclusion criteria: * age 18-75 years * self-reported diabetes type 2, with or without medication * regularly participate in grocery shopping exclusion criteria: * no access to bankid (a digital identification system commonly used in sweden), thus unable to consent to the study * fail to complete the run-in procedures.

Keywords: diet mobile health hba1c
monitoring trends in venous thromboembolism

Conditions: Blood Coagulation Disorders; Venous Thromboembolism; Cardiovascular Diseases

Summary: to describe time trends in the epidemiology of venous thromboembolism.

background: venous thromboembolism (vte) has been estimated to be the third most common cardiovascular disorder. frequently cited estimates of the incidence of vte, and its associated outcomes, are based on studies conducted more than a decade ago and only in hospitalized patients. contemporary data on the magnitude of this disorder, clinical profile of patients affected, acute and long-term outcomes, and use of different treatment strategies are needed given recent advances in diagnostic and therapeutic modalities. design narrative: the goals of the study are to collect population based data describing trends over time in the epidemiology of vte including its incidence, management, short and long-term recurrence rates, and mortality. the study will take place in residents of the worcester, massachusetts, metropolitan area, (2000 census = 477,800) and will examine changes over time in these and additional endpoints for patients with validated vte in 1998, 2000 and 2002 with a minimum follow-up of three years. complementing the community based surveillance of vte, newly diagnosed cases of vte occurring in members of the largest health maintenance organization (hmo) in central massachusetts between 1998 and 2002 will be identified. this cohort is tracked by an outpatient computer database allowing for the systematic collection of additional data on treatment practices and outcomes occurring outside of the hospital setting. the project will build on the investigators' clinical and epidemiological experience and on data collection methodologies used in the worcester deep vein thrombosis (dvt) study (1985-1989) and the ongoing worcester heart attack study. the medical records of worcester area residents diagnosed with vte and related diagnostic rubrics will be reviewed and validated according to pre-established diagnostic criteria. records for additional hospitalizations and death certificates will be reviewed to examine trends in long-term recurrence and survival rates through 2005. the results of this study will provide much needed current reformation about the epidemiology of vte and provide important data on current diagnostic and therapeutic strategies used in these patients. implementation of this registry will set the stage for systematic long-term surveillance of this medically important problem.

Eligibility criteria:
no eligibility criteria
use of platelet rich fibrin in addition to caf and sctg for treatment of gingival recession

Conditions: Gingival Recession

Summary: this research will be conducted in an attempt to achieve complete root coverage with physiologic probing depth and a harmonious view with the adjacent tissues using platelet rich fibrin in conjunction with coronally advanced flap and subepithelial connective tissue graft.

the study population will be divided into 2 groups: group 1: patients suffering from miller class i or ii gingival recession will be treated with a coronally advanced flap in conjunction with a sub-epithelial connective tissue graft. the patients should be non-smoker, medically free and above 18 years group 2: patients suffering from miller class i or ii gingival recession will be treated with a coronally advanced flap in conjunction with a sub-epithelial connective tissue graft and platelet rich fibrin. the patients should meet the same inclusion criteria mentionned above.

Eligibility criteria:
inclusion criteria: - 1) patients 18 years and older 2) buccal recession defects classified as either miller class i or ii gingival recession. 3) clinical indication and/or patient request for recession coverage 4) good oral hygiene exclusion criteria: - 1) miller class iii and iv gingival recession. 2) any systemic diseases or any medication. 3) pregnancy. 4) patients undergoing radiotherapy. 5) handicapped and mentally retarded patients. 6) current and former smokers as smoking is a contra-indication for plastic periodontal surgery . 7) teeth with cervical restorations, abrasion

Keywords: root coverage
evaluating progression of and diagnostic tools for primary ciliary dyskinesia in children and adolescents

Conditions: Primary Ciliary Dyskinesia

Summary: mucociliary clearance, in which mucus secretions are cleared from the breathing airways, is the primary defense mechanism for the lungs. inhaled particles, including microbes that can cause infections, are normally entrapped in mucus on the airway surfaces and then cleared out by the coordinated action of tiny hair-like structures called cilia. individuals with primary ciliary dyskinesia (pcd) have defective mucociliary clearance, which in turn leads to lung infections and disease. the purpose of this study is to determine how lung disease progresses over time in children and adolescents with pcd.

pcd is a rare genetic disorder in which impaired mucus clearance commonly results in chronic cough and infections in the airways, sinuses, and middle ears. long lasting airway infection ultimately leads to structural damage to the airways, known as bronchiectasis, and, in turn, loss of lung function. while pcd shares some similarities with the disease cystic fibrosis, it is important to distinguish pcd from cystic fibrosis. in particular, the age of onset and progression of pcd's clinical lung disease, including timing of specific microbial pathogen infections and bronchiectasis, remain poorly defined. the purpose of this study is to determine how lung disease progresses over time in children and adolescents with pcd. specific attention will be directed toward determining whether certain factors play a role in lung disease progression. the study will also evaluate diagnostic tools and quality of life among individuals with pcd. filling these gaps of knowledge may help to improve the clinical management of pcd in the future. this longitudinal study will last 5 years. there will be a total of 5 study visits, and these visits will occur yearly. each study visit will last 3 to 4 hours. all study visits will include a medical history review; physical exam; height, weight, and vital sign measurements; sampling of respiratory fluids and mucus; lung function tests; and questionnaires. the initial visit may also include using a probe to measure nasal nitric oxide levels and blood collection for genetic testing. study visits 1, 3, and 5 will also include blood collection for pregnancy testing and a high resolution computed tomography (hrct) scan of the chest to image the lungs. at the end of each month, participants will report any use of oral, inhaled, or intravenous antibiotics.

Eligibility criteria:
inclusion criteria: * diagnosis of pcd or probable pcd. more information about the criteria for a pcd diagnosis can be found in the protocol. * parent or guardian willing to provide informed consent exclusion criteria: * inability to attend follow-up appointments * previously received lung transplant * any disease that may have significant impact on lung function (e.g., severe congenital heart disease, severe scoliosis), respiratory infections (e.g., aids), or overall health status (e.g., cancer, end-stage kidney disease) * pregnant or breastfeeding

Keywords: kartagener syndrome
prosenza: prospective multi-centre study of prognostic factors in mcrpc patients treated with enzalutamide.

Conditions: Advanced Prostate Cancer; Castration Resistant; Enzalutamide

Summary: prosenza is a prospective multicentre observational study in metastatic castration-resistant prostate cancer (mcrpc), designed to explore prognostic biomarkers in patients undergoing treatment with enzalutamide

this study is a prospective biomarker study of patients with mcrpc undergoing treatment with enzalutamide as standard of care treatment. the participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.

Eligibility criteria:
inclusion criteria: 1. male age ≥ 18 years 2. histologically confirmed adenocarcinoma of the prostate 3. ecog performance status ≤ 2 4. castration resistance must be documented with surgical or medical castration with serum testosterone \< 50 ng/ml (\< 2.0 nm). 5. men diagnosed with at least one metastatic lesion on ct or bone scan. 6. documented biochemical and/or radiographic progression to previous treatment according to pcwg2 criteria. 7. patients who are candidates for standard of care treatment with enzalutamide 160 mg every 24 hours. 8. availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy and/or radical prostatectomy. 9. acceptable hematological, hepatic and renal functions. exclusion criteria: 1. previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free or those diagnosed with skin cancers (of non-melanoma type) or excised in situ carcinomas. 2. any condition or reason that, in the opinion of the investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data

Keywords: metastatic castration resistant prostate cancer enzalutamide biomarkers
predictors of postoperative pain following oocyte retrieval for assisted reproduction

Conditions: Oocyte Retrieval; Postoperative Pain

Summary: the central objective of this study will be to evaluate the relationship between estrogen levels and the pain following oocyte retrieval in women undergoing in vitro fertilization.

subject will undergo standard clinical protocols for the entire oocyte stimulation cycle and all assisted reproductive procedure decisions and algorithms will be decided entirely independent of this study. the anesthetic and postoperative pain regimens will use the same agents and dose ranges used in clinical standard practice; however, the regimens will be standardized, so as to limit confounding variables. the study regimen for anesthesia will differ from the current, clinical standard by the mandated use of actual body weight (in current practice, actual, adjusted ideal, or ideal body weights are used), the use of fentanyl 1 mcg/kg iv (instead of 100 mcg for everyone), and the standardization of postoperative analgesia (noted below). the total amount of fentanyl, propofol, and postoperative drugs will be recorded. postoperative analgesia will be standardized based on the subject's self reported verbal analogue score (vas) and the timing of the report. the agents and timing used below differ from the current clinical standard by assessing vas and responding with a certain regimen.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i to iii health status (moderate systemic disease), * age between 18 and 50 yrs * undergoing oocyte retrieval with intravenous general anesthesia. exclusion criteria: * refuse or withdraw their consent * fail to adequately respond to ivf stimulations medications, and thus are not eligible for oocyte retrieval.

Keywords: assisted reproduction postoperative pain opioid
the impact of phase i cardiac rehabilitation on the prognosis of ami patients after pci

Conditions: Acute Myocardial Infarction; Phase I Cardiac Rehabilitation

Summary: previous research has confirmed that patients undergoing percutaneous coronary intervention (pci) can benefit from cardiac rehabilitation programs. however, there is a paucity of studies on phase i cardiac rehabilitation commenced within three days following pci in patients with acute myocardial infarction (ami). consequently, the objective of the study is to demonstrate whether phase i cardiac rehabilitation can improve the prognosis at 12 months when compared with the control group. the primary endpoint is the seattle angina questionnaire (saq) score at 12 months for the patients. the principal hypothesis of the study is that phase i cardiac rehabilitation will improve the long-term prognosis for ami patients at 12 months after pci.


Eligibility criteria:
inclusion criteria: 1. patients with ami (including stemi and nstemi) who were treated in the ccu (coronary care unit) for more than 12 hours after emergency pci; 2. patients who are expected to meet the discharge criteria without the need for repeat pci during the current hospital stay after pci; 3. no chest pain episodes within 8 hours, with no recurrence of myocardial infarction; remained hemodynamically stable; 4. no further increase in serum levels of cardiac biomarkers such as creatine kinase -mb (ck-mb) and cardiac troponins (ctn). exclusion criteria: 1. patients with killip class iii or higher, or symptoms and signs of acute pulmonary edema and respiratory distress; 2. malignant arrhythmias that cause hemodynamic instability and potentially life-threatening conditions; 3. mechanical lesions such as ventricular wall rupture, valve or tendon rupture; 4. patients who have not yet been weaned off ecmo, iabp, temporary pacemakers, crrt; 5. patients with liver or kidney dysfunction (transaminase exceeded three times the upper limit of normal; egfr\<30 ml/(min·1.73m\^2)) or advanced malignant tumors; 6. patients who cannot undergo exercise rehabilitation due to orthopedic or psychiatric diseases; 7. patients with language impairment; 8. patients currently undergoing systematic training or participating in other clinical trials without reaching the primary endpoint collection time; 9. researchers believe that patients are not suitable for participation in this study or have not obtained an informed consent form.
using 3.3mm screw tap and cutting resistance to evaluate bone quality around dental implant

Conditions: Jaw, Edentulous, Partially; Mouth, Edentulous

Summary: osseointegrated root form implants have been applied successfully in treating fully and partially edentulous patients and patients with single tooth missing. however, the success rate of osseointegrated dental implants was not as good in patients with poor bone quality. the reasons are believed that poor bone quality reduces the initial stability of dental implants and then reduces the success rate. for increasing initial stability of dental implants, some technical modifications are suggested in literature. however, due to lack of an objective method to evaluate bone quality, they are controversial. the purposes of this clinical study are to develop a standard procedure which using cutting resistance measured by osseocare in surgery to evaluate the bone quality and to compare with the clinical experiences of oral surgeons. the objective outcome, initial stability of dental implant, is measured with osstell. the analyzed results are also helpful for less experienced surgeons.

materials \& methods: 1. patient eligibility: six implant surgeons will assist the experiment. the subjects are patient who will receive dental implant treatment in dental department of ntuh. sixty subjects are offered by six surgeons. they must fully fill the requirements as following

Eligibility criteria:
inclusion criteria: * no major systemic diseases * mouth opening: \> 35 mm * missing teeth at anterior or premolar area and willing to restored by implantation exclusion criteria: * uncomfortable or other condition occurring in the surgical procedure make the measuring unacceptable